Xeris Biopharma Files 8-K on Financials
Ticker: XERS · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Xeris Biopharma just dropped an 8-K detailing their financials - check it out!
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report period and date of earliest event both being January 10, 2025. The company is incorporated in Delaware and headquartered in Chicago, Illinois.
Why It Matters
This filing provides investors with updated financial information and operational results for Xeris Biopharma Holdings, Inc., crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of Report
- Chicago, Illinois (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When is the earliest event reported in this filing?
The earliest event reported is dated January 10, 2025, which is also the date of the report.
What is Xeris Biopharma Holdings, Inc.'s principal executive office address?
The principal executive offices are located at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SIC code for Xeris Biopharma Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Xeris Biopharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-10 07:17:43
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share XERS The Nasdaq Global Select
Filing Documents
- xers-20250110.htm (8-K) — 28KB
- pressreleaseissuedbyxerisb.htm (EX-99.1) — 16KB
- image_0a.jpg (GRAPHIC) — 18KB
- 0001867096-25-000017.txt ( ) — 225KB
- xers-20250110.xsd (EX-101.SCH) — 2KB
- xers-20250110_def.xml (EX-101.DEF) — 15KB
- xers-20250110_lab.xml (EX-101.LAB) — 26KB
- xers-20250110_pre.xml (EX-101.PRE) — 15KB
- xers-20250110_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 10, 2025, Xeris Biopharma Holdings, Inc. (the "Company") issued a press release announcing certain of its financial preliminary results for the fourth quarter and full year ended December 31, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed pursuant to Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release issued by the Company dated January 10 , 202 5 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 Xeris Biopharma Holdings, Inc. By: /s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer